As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to their future outlook. In the case of Pfizer Limited (NSE:PFIZER), it is a dependable dividend-paying company that has been able to sustain great financial health over the past. In the following section, I expand a bit more on these key aspects. For those interested in understanding where the figures come from and want to see the analysis, take a look at the report on Pfizer here.
Excellent balance sheet average dividend payer
PFIZER's ability to maintain an adequate level of cash to meet upcoming liabilities is a good sign for its financial health. This suggests prudent control over cash and cost by management, which is an important determinant of the company’s health. PFIZER appears to have made good use of debt, producing operating cash levels of 39.12x total debt in the prior year. This is a strong indication that debt is reasonably met with cash generated.
For those seeking income streams from their portfolio, PFIZER is a robust dividend payer as well. Over the past decade, the company has consistently increased its dividend payout, reaching a yield of 0.7%.
For Pfizer, I've put together three fundamental aspects you should look at:
- Future Outlook: What are well-informed industry analysts predicting for PFIZER’s future growth? Take a look at our free research report of analyst consensus for PFIZER’s outlook.
- Historical Performance: What has PFIZER's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of PFIZER? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.